Evaluation of U.S. Commercial-Off-the-Shelf Hand-Held Assays to Detect Opiate Pain Reliever Compounds in Multiple Biofluids
Technical Report,01 Jun 2014,31 May 2015
ECBC Aberdeen Proving Ground United States
Pagination or Media Count:
Law enforcement, first responders, and the DOD community require fast, reliable, and inexpensive screening technologies for drugs and other compounds that can pose a threat to safety and health. However, there are gaps in the ability to detect many compounds in the field. For some compounds, the problem may be poor screening tests that can include false positives or impractical limits of detection, and others may have no field tests at all. In this study, we evaluated the potential for several U.S. commercial-off-the-shelf COTS hand-held assays HHAs to detect members of the opiate pain reliever class of compounds. Each HHA was developed for urine testing, and each came with its own stated claims of sensitivity and specificity. We evaluated the performance of three HHAs and tested for sensitivity and specificity to compounds in buffer conditions and in exposed animal biofluids. All HHAs successfully detected Compounds 1 and 2 in urine to varying degrees, some showed some detection of Compound 1 in saliva, and none detected Compound 3. In collaboration with the leading HHA company from this study, future work will functionalize and improve a COTS HHA platform for enhanced sensitivity of detection of Compound 1 in saliva and plasma.